The Subject Expert Committee (SEC) according to India’s drug controller has provided its nod to Bharat Biotech for performing phase 2 & 3 clinical prosecutions.
We use cookies to ensure you have the best browsing experience on our website. By using our site, you
acknowledge that you have read and understood our
Cookie Policy &
Privacy Policy.